Stay updated with breaking news from Christopherj Senner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective […]
Candriam S.C.A. lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,536,921 shares of the biotechnology company’s stock after selling 706,117 shares during the quarter. Candriam […]
Exelixis (NASDAQ:EXEL – Free Report) had its price target raised by JMP Securities from $24.00 to $27.00 in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. EXEL has been the subject of a number of other research reports. StockNews.com initiated […]
South Dakota Investment Council grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 19.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 185,162 shares of the biotechnology company’s stock after purchasing an additional 30,000 shares during the period. South Dakota […]
South Dakota Investment Council boosted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 19.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 185,162 shares of the biotechnology company’s stock after purchasing an additional 30,000 shares during the period. […]